Rapport Therapeutics (RAPP) Operating Income (2023 - 2026)
Rapport Therapeutics (RAPP) posted quarterly Operating Income of -$24.2 million for Q1 2026, up 10.67% year-over-year from -$21.9 million in Q1 2025, and up 37.12% quarter-over-quarter from -$38.5 million in Q4 2025.
Rapport Therapeutics (RAPP) Operating Income (2023 - 2026) Analysis & Trends
Rapport Therapeutics (RAPP) has reported Operating Income for 4 consecutive years, with -$24.2 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Operating Income rose 10.67% year-over-year to -$24.2 million; the TTM figure through Mar 2026 stood at -$122.2 million (down 31.31% YoY), while the FY2025 annual figure was -$125.1 million, down 50.62% from the prior year.
- Operating Income advanced to -$24.2 million in Q1 2026 per RAPP's latest filing, from -$38.5 million in the prior quarter.
- Across five years, Operating Income topped out at -$6.6 million in Q2 2023 and bottomed at -$38.5 million in Q4 2025.
- Historically, Operating Income has averaged -$21.9 million across 4 years, with a median of -$22.6 million in 2024.
- Annual changes were most pronounced in 2024 — Operating Income slumped 213.73% — and 2026, when it advanced 10.67%.
- Rapport Therapeutics' Operating Income stood at -$14.8 million in 2023, then sank by 58.99% to -$23.5 million in 2024, then sank by 63.72% to -$38.5 million in 2025, then soared by 37.12% to -$24.2 million in 2026.
- Business Quant data shows RAPP's Operating Income at -$24.2 million in Q1 2026, -$38.5 million in Q4 2025, and -$30.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 493.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -505.13 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 325.05 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -3,158.03 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 133.12 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 231.44 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.55 Mn |
| 10 | Rapport Therapeutics | 2.27 Bn | 2.27 Bn | - | -60.81 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -60.81 Mn |
| Mar 31, 2026 | -24.22 Mn |
| Dec 31, 2025 | -38.51 Mn |
| Sep 30, 2025 | -29.99 Mn |
| Jun 30, 2025 | -29.50 Mn |
| Mar 31, 2025 | -27.11 Mn |
| Dec 31, 2024 | -23.52 Mn |
| Sep 30, 2024 | -21.64 Mn |
| Jun 30, 2024 | -20.80 Mn |
| Mar 31, 2024 | -17.09 Mn |
| Dec 31, 2023 | -14.79 Mn |
| Sep 30, 2023 | -9.56 Mn |
| Jun 30, 2023 | -6.63 Mn |